All In Biotech

Drug Trial Radar · NCT00038948

Study Comparing Conversion to Sirolimus vs. Continued Use of Calcineurin Inhibitors in Kidney Transplant Recipients

A Randomized, Open-label, Comparative Evaluation of Conversion From Calcineurin Inhibitors to Sirolimus Versus Continued Use of Calcineurin Inhibitors in Renal Allograft Recipients

Last checked: Nov 20, 2026Latest source record: May 14, 2010 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 830 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

830

Actual

Start

Jan 2002

Primary completion

May 2008

Study completion May 2008

Sponsor

Sponsor type
Industry
First posted
Jun 7, 2002

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 13 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to determine the effect of conversion from calcineurin inhibitor to sirolimus based therapy on renal function.

Conditions

  • Renal Transplantation

Interventions

  • SirolimusDrug

    Sirolimus, Cyclosporine A \& Tacrolimus are concentration controlled

  • tacrolimusDrug

  • Cyclosporine ADrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Nankivell Glomerular Filtration Rate (GFR)Time frame: 52 weeks

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.